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Background Nurse-led integrated care is expected to improve outcome of patients with atrial fibrillation compared with usual-




We randomized 1375 patients with atrial fibrillation (64 ± 10 years, 44% women, 57% had CHA2DS2-VASc >_ 2) to
receive nurse-led care or usual-care. Nurse-led care was provided by specialized nurses using a decision-support
tool, in consultation with the cardiologist. The primary endpoint was a composite of cardiovascular death and car-
diovascular hospital admissions. Of 671 nurse-led care patients, 543 (81%) received anticoagulation in full accord-
ance with the guidelines against 559 of 683 (82%) usual-care patients. The cumulative adherence to guidelines-
based recommendations was 61% under nurse-led care and 26% under usual-care. Over 37 months of follow-up,
the primary endpoint occurred in 164 of 671 patients (9.7% per year) under nurse-led care and in 192 of 683
patients (11.6% per year) under usual-care [hazard ratio (HR) 0.85, 95% confidence interval (CI) 0.69 to 1.04,
P = 0.12]. There were 124 vs. 161 hospitalizations for arrhythmia events (7.0% and 9.4% per year), and 14 vs. 22
for heart failure (0.7% and 1.1% per year), respectively. Results were not consistent in a pre-specified subgroup
analysis by centre experience, with a HR of 0.52 (95% CI 0.37–to 0.71) in four experienced centres and of 1.24
(95% CI 0.94–1.63) in four less experienced centres (P for interaction <0.001).
...................................................................................................................................................................................................
Conclusion Our trial failed to show that nurse-led care was superior to usual-care. The data suggest that nurse-led care by an
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Patients with atrial fibrillation are usually seen by a cardiologist. To
improve cardiovascular outcomes in these patients, guidelines advo-
cate multidisciplinary management, patient empowerment and
shared decision-making.1–3. Also, clinical care for atrial fibrillation
provided by a mono-disciplinary specialist may become unaffordable.
One manner to implement improvements in patient care is through
the co-ordination by a nurse specialized in atrial fibrillation. Nurse-
led care is expected to be less resource-intensive and potentially
reduces events over and above usual-care. However, it is uncertain
whether in clinical practice nurse-led care is effective since data are
limited and studies do not provide conclusive evidence.4–9
Therefore, we conducted a multicentre, randomized trial, RACE 4
(Rate Control vs. Electrical Cardioversion Trial 4—Nurse-led Care
vs. Usual-care), to find out whether in patients newly referred for
management of atrial fibrillation, nurse-led care would be superior to
usual-care provided by a cardiologist in reducing cardiovascular mor-
tality and cardiovascular hospitalization.
Methods
We conducted this superiority trial in the cardiology departments of
eight hospitals in the Netherlands, including two academic hospitals, five
non-academic teaching hospitals and one non-teaching hospital. Among
these, four hospitals had previous experience with nurse-led care. The
trial was initiated by the investigators and co-ordinated by the Maastricht
University Medical Centre. The trial was approved by the institutional re-
view board at the medical centre; the review board at each of the partici-
pating sites approved the protocol (Supplementary material online). All
the patients provided written informed consent. An independent data
and safety monitoring board reviewed independently and in a blinded
fashion the accumulating safety and efficacy data at regular intervals during
the trial. The trial was supported by Netherlands healthcare insurance
companies (DSW, ACHMEA, and CZ), Boehringer Ingelheim, Bayer,
Pfizer, Bristol-Myers Squibb, and Daiichi-Sankyo, but all had no role in the
design or execution of the trial; company representatives did not review
the protocol or the manuscript. The writing committee wrote the manu-
script, and all the steering committee members made the decision to sub-
mit it for publication. The authors had unrestricted access to the data and
vouch for the accuracy and completeness of the data and analyses and for
the fidelity of the trial to the protocol.
Study participants
From December 2012 through November 2017, we enrolled adults
(>_18 years of age) with first-detected atrial fibrillation referred to the out-
patient cardiology clinic by their primary care physician or a non-
cardiology specialist for cardiological management. All patients were in a
stable condition and qualified as being candidates for either nurse-led
care or usual-care. Patients were excluded if they had an episode of un-
stable heart failure or acute coronary syndrome within 3 months before
inclusion. Patients who recently underwent cardiac surgery or in whom
cardiac surgery was planned were excluded. Further details regarding the
inclusion and exclusion criteria are provided in Supplementary material
online, Table S1.
Randomization and treatment
After providing written informed consent, all patients were randomly
assigned in a 1:1 ratio stratified by centre to nurse-led care or usual-care
provided by a cardiologist. Randomization was performed with the use of
a centralized Web-based system. After randomization, the first visit was
planned with the specialized nurse or the cardiologist per randomized
group. Nurse-led care included treatment of patients by a specialized
nurse using guidelines-based decision-support software (CardioConsult
AFVR , Curit Software, Groningen, The Netherlands) ensuring comprehen-
sive treatment of atrial fibrillation and associated conditions, covering car-
diovascular risk factor management, antithrombotic treatment, rate
control, and rhythm control4,10,11 (Supplementary material online, Figure
S1). Complete cardiological diagnostic tests and treatments were
installed during the first outpatient visit. All test results were extensively
discussed, and treatments adapted as needed and confirmed onsite with
the supervising cardiologist, all during the first visit. To enhance patients’
adherence the nurse provided psychosocial support as well as personal-
ized education on pathophysiology, symptoms, and complications of atrial
fibrillation. Usual-care consisted of routine outpatient management by a
cardiologist without a specified clinical pathway. An overview of nurse-
led care and usual-care is provided in Supplementary material online,
Figure S2.
Follow-up
Follow-up visits under nurse-led care were achieved at 3, 6, and
12 months, and yearly thereafter. Blood pressure and the electrocardio-
gram were recorded, and psychosocial support and educational interven-
tion were repeated during follow-up visits. Medication was adjusted as
needed. Upon the nurse’s request, the cardiologist provided supervision
during follow-up visits. Changes in anticoagulation therapy, or in rate and
rhythm control were done in consultation with the cardiologist. At
patients’ request, additional visits either by telephone or in-person were
performed at the outpatient department. Patients in the usual-care arm
were followed yearly or were referred back to their primary care phys-
ician, all at the discretion of the attending cardiologist. Follow-up was ter-
minated within a maximum period of 5 years and 10 months or until 1
October 2018, whichever came first.
Endpoints
The primary endpoint was a composite of cardiovascular death and hos-
pital admission for arrhythmias, heart failure, thromboembolic events,
major bleeding, acute coronary syndrome, or life-threatening effects of
drugs. Definitions of the components of the primary Endpoint are
reported in Supplementary material online, Table S2. Secondary end-
points included the level of implementation of care according to the
guidelines assessed after the first visit, patients’ knowledge on atrial fibril-
lation using the Netherlands Knowledge Scale on Atrial Fibrillation, 12
quality of life using the University of Toronto Atrial Fibrillation Severity
Scale (AFSS)13, the Patient Activation Measure self-management score14,
and cost-effectiveness. All primary endpoint events were adjudicated by
an independent clinical endpoint committee (not aware of the random-
ized treatment assignments) that used the above-mentioned definitions
of the components of the primary endpoint. A complete overview of all
secondary endpoints of the trial is listed in the Supplementary material
online, Table S3.
Statistical analysis
The primary hypothesis of the trial was that nurse-led care would be su-
perior to usual-care with respect to the primary endpoint. The sample
size determination was event-driven. The design assumptions included a
2 years event rate of 11.2% for nurse-led care and 16.0% for usual-care.
We calculated that 246 composite primary endpoints would provide the
trial with 80% power to statistically detect the expected treatment bene-
fits at a two-sided significance level of 0.05. Monitoring of the occurrence
































































































of the primary endpoints over time indicated that 1375 patients with a
minimum follow-up of 1 year, would provide at least 246 endpoints.
Analyses were performed according to the intention-to-treat prin-
ciple. Patients without any electrocardiographic documentation of atrial
fibrillation before the first visit were excluded from the analysis, as were
patients with full withdrawal of informed consent.
Event rates over time were displayed using the Kaplan–Meier method.
Hazard ratios (HR) with 95% confidence intervals (CI) and P-values were
calculated using the Cox proportional hazards model. Follow-up of the
patients was censored at the study termination as defined above or at the
last day of known clinical status. All reported secondary and subgroup
analyses were pre-specified. Categorical variables were tested using
Fisher’s exact test, and between-group differences for proportions and
95% CIs were calculated with the Wald Z method. Continuous variables
were tested with the independent two sample t-test.
Results
Patients
Of the 1375 patients who had undergone randomization, 686 were
assigned to nurse-led care and 689 to usual-care, and 671 and 683
were included in the primary analysis, respectively (Supplementary
material online, Figure S3). Overall the characteristics of the patients
at inclusion were well-balanced between the two groups (Table 1).
The mean (±SD) age was 64± 10 years, 891 patients (66%) were
male, 766 (57%) had an increased risk of stroke as reflected by a
CHA2DS2-VASc score of two or higher and 106 patients (8%) had
risk of bleeding as suggested by a HAS-BLED score of three or higher.
For extended baseline characteristics see Supplementary material
online, Table S4.
Endpoints
Over a median follow-up of 37 months, the primary endpoint
occurred in 164 of 671 patients (9.7% per year) under nurse-led care
and in 192 of 683 patients (11.6% per year) under usual-care (HR
0.85, 95% CI 0.70–to 1.05, P = 0.12; Take home figure, panel A). There
were seven vs. three patients with cardiovascular death (0.4% and
0.1% per year), 124 vs. 161 with hospitalizations for arrhythmic
events (7.0% and 9.4% per year), and 14 vs. 22 patients with heart fail-
ure hospitalization (0.7% and 1.1% per year), in the nurse-led vs.
usual-care group, respectively (Table 2). Non-cardiovascular mortal-
ity amounted 14 (2%) and 14 (2%) patients, and cardiovascular emer-
gency department visits occurred in 86 (13%) and 72 patients (11%),
all respectively.
The adherence to seven guidelines-based recommendations on
diagnostic procedures and treatments, counting each recommenda-
tion separately, was 61% under nurse-led care and 26% under usual-
care. For virtually all patients at least two recommendations were
implemented whilst nurse-led care performed significantly better
than usual-care with regards to implementation of three or more rec-
ommendations (Fig. 1A). There was no difference between nurse-led
care and usual-care concerning implementation of oral anticoagula-
tion or rhythm control therapy (Fig. 1B). However, the implementa-
tion of diagnostic procedures (echocardiography, blood pressure
measurements, thyroid and renal function testing and assessment of
glucose level) was much better under nurse-led care than under
usual-care. Therefore, the low cumulative adherence under usual-
care (Fig. 1A) relates particularly to lack of cardiovascular risk assess-
ment including measuring blood pressures, renal function and glucose
intolerance (Fig. 1B).
The scores on the knowledge scale were not significantly different
at 1 year of follow-up between nurse-led care and usual-care
(7.3± 1.6 and 7.4 ± 1.5, difference -0.08, 95% CI, -0.2 to 0.3), as were
AFSS quality of life scores (4.8± 5.2 and 5.1± 5.4, difference 0.35,
95% CI, -0.36 to 1.07), and scores on patient self-management
(61.6 ± 17.1 and 61.8 ± 15.7, difference 0.2, 95% CI -2.0 to 2.4), all re-
spectively. At 2 years of follow-up, nurse-led treatment was marginal-
ly more costly without a significant difference in QALYs
(Supplementary material online, Figure S4).
Between-group differences in the occurrence of the primary end-
point under nurse-led care and usual-care in various pre-specified
subgroups are shown in Figure 2 and Take home figure, panel B. There
was heterogeneity for centre experience which showed a HR favour-
ing nurse-led care in experienced centres (HR 0.52, 95% CI 0.37–to
0.71), and a HR disfavouring nurse-led care in less-experienced
centres (HR 1.24, 95% CI 0.94–1.63), with a P-value for interaction of
<0.001. Other treatment effects were consistent among the other
predefined subgroups. Data illustrating differences in centre experi-
ence are provided in Supplementary material online, Figures S5, S6
and Tables S5, S6.
Treatment
There was no difference between treatment groups concerning im-
plementation of anticoagulation. In total, 543 (81%) nurse-led care
and 559 (82%) of usual-care patients were appropriately treated with
oral anticoagulation. On the other hand, 30 (4.5%) nurse-led and 31
(4.5%) usual-care patients were treated with oral anticoagulants with-
out a calculated stroke risk (i.e. over-treatment) whereas in 98
(14.6%) and 93 (13.6%) patients anticoagulants were inappropriately
withheld (i.e. under-treatment), respectively.
The use of rate control medication did not differ between groups
(Supplementary material online, Table S7). The mean heart rate at
3 months, i.e. after installing rate control therapy was 88 ± 17.7 and
88 ± 18.9 beats per minute (mean difference 0.4, 95% CI -4.4 to5.1)
under nurse-led and usual-care, respectively. Rhythm control was
applied more often in the nurse-led care group compared with usual-
care. The number of consultations per treatment group is shown in
Supplementary material online, Table S8.
Discussion
We found that among patients recently referred for management of
first-detected atrial fibrillation, nurse-led care did not significantly re-
duce the risk of cardiovascular death or hospital admission compared
with usual-care. Remarkably, there was a lack of effect of nurse-led
care on patient knowledge and quality of life. Nevertheless, explora-
tory analyses suggested that in experienced centres, nurse-led care
was better than usual-care. Given the comparable event rates during
the entire follow-up between the two approaches, nurse-led care is a
safe manner of providing care for patients with atrial fibrillation.
Guidelines-based recommendations for the examination of the
aetiology of atrial fibrillation, associated cardiovascular conditions,
stroke prevention, and rhythm control therapy were well-
































..implemented under nurse-led care and less well under usual-care
(Fig. 1). Despite this difference, we did not find a statistically significant
impact on the primary endpoint. Note that the implementation dif-
ference was specifically found for recommendations which may lack
direct impact on our primary outcome. In contrast, recommenda-
tions directly preventing severe events, including stroke or ventricu-
lar proarrhythmia, were fulfilled equally. The profile of our patients in
terms of cardiovascular risk was mild with CHA2DS2-VASc score <2
in 43% of patients, and the overall event rate was accordingly low.
Under those circumstances a lack of implementation may not
immediately affect outcome. Conversely, when patients exhibit
more co-morbidities, correct implementation of diagnostic and
treatment procedures as warranted by nurse-led care, may
become crucial.5,6,15–17
The primary endpoint was driven by admission for arrhythmias,
notably atrial fibrillation, which occurred much less under nurse-
led care. Reasons for a lower hospitalization rate for arrhythmia
recurrence may include better reassurance of patients by the
nurse,18 more patients on rhythm control therapies, or better
rate control in addition to optimal implementation of diagnostic
procedures and treatment of co-morbidities.19,20 In nurse-led
care, nurses spent more time on informing patients
(Supplementary material online, Table S8), including providing re-
assurance about the inconvenience and presumed risks of recur-
rences of atrial fibrillation. Focus on ameliorating atrial fibrillation
symptoms is important and in that respect reducing heart rate
during a recurrence or in patients with chronic atrial fibrillation is
important.21 A better rate control did, however, not play a role,
since use of rate control medication did not differ and heart rates
while in atrial fibrillation were similar in both approaches. In con-
trast, under nurse-led care, there was a higher use of rhythm con-
trol therapies. The relatively low-risk profile of patients gave
....................................................................................................................................................................................................................
Table 1 Characteristics of the patients at baseline, according to the assigned treatment
Characteristic Nurse-led care (n 5 671) Usual-care (n 5 683)
Age (years) 64 ± 10 64 ± 11
Male sex, no. (%) 450 (67) 441 (65)
Duration of AF (days)a 14 (7–22) 13 (7–21)
Paroxysmal/non-paroxysmal AF, no. (%) 410 (61)/166 (25) 429 (63)/140 (20)
Symptoms at first visit outpatient clinic, no. (%) 324 (48) 319 (47)
Hypertension, no. (%) 329 (49) 316 (46)
History of heart failure, no. (%) 93 (14) 66 (10)
Diabetes, no. (%) 72 (11) 59 (9)
Ischaemic stroke or transient ischaemic attack, no. (%) 56 (8) 42 (6)
Haemorrhagic stroke, no. (%) 2 (0) 2 (0)
Coronary artery disease, no. (%) 40 (6) 37 (5)
Valvular heart disease, no. (%) 22 (3) 36 (5)
Peripheral artery disease, no. (%) 19 (3) 8 (1)
Hyperthyroidism, no. (%) 14 (2) 6 (1)
Chronic obstructive pulmonary disease, no. (%) 63 (9) 62 (9)
Malignancy, no. (%) 53 (8) 73 (11)
CHA2DS2-VASc score,
b no. (%)
0 162 (24) 173 (25)
1 122 (18) 131 (19)
>_2 387 (58) 379 (56)
HASBLED-score, no. (%)
>_3 49 (7) 57 (8)
Body mass index, kg/m2 28 ± 5 28 ± 5
Systolic blood pressure, mmHg 139 ± 20 143 ± 19
Diastolic blood pressure, mmHg 83 ± 11 84 ± 1
Echocardiographic left atrial size, long axis, mm 40 ± 6 40 ± 6
Left ventricular ejection fraction, % 55 ± 9 55 ± 9
Plus-minus values are means ± SD. Congestive heart failure, hypertension, an age of 65–74 years, diabetes, and vascular disease are each assigned one point, and previous stroke
or transient ischaemic attack and an age >75 years are assigned two points. The HAS-BLED score is a measure of bleeding risk in patients with AF on anticoagulants, with a
score ranging from 0 to 9 and higher scores indicating greater risk. Hypertension, abnormal renal function, abnormal liver function, previous stroke, previous bleeding, labile
international normalized ratio (INR), age over 65 years, prior alcohol, or drug usage and use of antiplatelet drugs or non-steroidal anti-inflammatory drugs are each assigned
one point. Echocardiographic data were available in 94% of patients in nurse-led care and 81% in usual-care. Numbers do not always add up to 100% for characteristics not
listed or missing variables at baseline.
aMedian, 25–75% range.
bThe CHA2DS2-VASc score is a measure of the risk of stroke in patients with AF, with scores ranging from 0 to 9 and higher scores indicating a greater risk.
AF, atrial fibrillation; TIA, transient ischaemic attack.

















ample opportunity to implement rhythm control safely. There
was no significant issue with appropriate application of guidelines-
based rules for providing rhythm control in both groups, but
rhythm control therapy was implemented more frequently by the
nurse aiming to ameliorate arrhythmia symptoms. An effective
understanding of the goals (and explanation of the risks and what
to expect from rhythm control therapy) may have reduced the
need for hospital admissions, especially when the patient under-
stands that a recurrence does not equal treatment failure or need
for immediate intervention.18
....................................................................................................................................................................................................................
Table 2 Primary endpoint
Endpoint Nurse-led care (n 5 671) Usual-care (n 5 683)
Composite endpoint, no. (%) 164 (24) (9.7% per year) 192 (28) (11.6% per year)
Cardiovascular death 7 (1.0) (0.4% per year) 3 (0.4) (0.1% per year)
Cardiac arrhythmic, no. (%) 1 (0.1) 1 (0.1)
Vascular non-cardiac, no. (%) 6 (0.9) 2 (0.3)
Cardiovascular hospitalizations
Arrhythmic events, no. (%) 124 (18.5) (7.0% per year) 161 (23.6)(9.4% per year)
Atrial fibrillation 115 (17.1) 138 (20.2)
Atrial flutter 4 (0.6) 12 (1.8)
Supraventricular arrhythmia 0 (0.0) 4 (0.6)
Syncope 11 (1.6) 14 (2.0)
Sustained ventricular tachycardia 1 (0.1) 2 (0.3)
Heart failure, no. (%) 14 (2.1) (0.7% per year) 22 (3.2) (1.1% per year)
Acute coronary syndrome, no. (%) 7 (1.0) (0.4% per year) 11 (1.6) (0.6% per year)
Ischemic TEC, no. (%) 15 (2.2) (0.8% per year) 12 (1.8) (0.6% per year)
Stroke/TIA 16 (2.4) 13 (1.9)
Systemic embolism 0 (0.0) 1 (0.1)
Major bleeding, no. (%) 13 (1.9) (0.7% per year) 10 (1.5) (0.5% per year)
Life-threatening effects of drugs, no. (%) 5 (0.7) (0.3% per year) 3 (0.4) (0.1% per year)
The tabulation of the composite primary endpoint includes the first event for each patient, whereas the tabulations of component end points include all such events. More ex-
tensive information on endpoints in subgroups is presented in the Supplementary material online, Table S4.
TEC, thromboembolic complications; TIA, transient ischaemic attack.
Take home figure (A) Primary endpoint of the trial. (B) The incidence of the primary endpoint over time in experienced (B1) and less-experi-
enced centres (B2).




















..Being anchored to the nurse, patients may have improved their
health behaviour just because they know that the nurse closely fol-
lows their performance and checks their knowledge of atrial fibrilla-
tion (Hawthorne effect).22 This effect is, in fact, desirable and should
be considered an integral part of nurse-led care. On the other hand,
in view of the lack of an effect of education on knowledge of atrial fib-
rillation, such Hawthorne effect may—unfortunately—not have been
large in the present study. If anything, the effects of nurse-led care
may have been diluted because the cardiologists in our study pro-
vided better usual-care because they were aware of their participa-
tion in the trial (annulling Hawthorne effect in the control group).
Nevertheless, generally at most only half of attending cardiologists
are experienced and, therefore, education has become a key both for
cardiologists and allied professionals23.
Nurse-led care was implemented significantly better than usual-
care but it was not perfect, especially not on anticoagulation. Almost
Figure 2 Subgroup analyses of the primary endpoint. AF, atrial fibrillation; BMI, body mass index; EHRA, European Heart Rhythm Association
score.
Figure 1 (A) Cumulative adherence counting the percentage of patients in whom at least 1–7 guidelines recommendations were applied. (B)
Adherence to specific recommendations from the guidelines. For definitions of appropriateness of application of guidelines recommendations see
Supplementary material online, Figure S2). The Wald Z method was used to calculate rate differences and 95% confidence intervals. BP, blood pres-
sure; Echo, echocardiogram; OAC, oral anticoagulation; Rh Ctrl, rhythm control; TSH, thyroid stimulating hormone.
































































































15% of patients were under-treated and up till 5% of patients
were over-treated. This is remarkable especially since nurses
received an electronic advice on antithrombotic treatment. Patients’
preference24 certainly may have played a role, but equally important
is the shared decision-making process between nurse and doctor,
which may have led to defective antithrombotic management on the
advice of the cardiologist.8 This interpretation is supported by the
fact that the extent of over- and under-treatment was the same in
both arms of the study.
Heterogeneity between centres was considerable concerning ex-
perience in nurse-led care since four centres were proficient includ-
ing the presence of experienced nurses and well-interacting
supervising doctors having at least 1 year of team experience in
nurse-led care, and four centres with less experience. The variation
seen with implementation of nurse-led care in our study reflects the
absence of a consensus description of what integrated care for atrial
fibrillation should include.25,26 It also supports the notion that training
is key to obtain excellent results and especially a focus on team-
based integrated care approaches seems important2,8,27.
Limitations
The difference in site experience led to heterogeneity in the treat-
ment benefit which may impede the interpretation of the trial. The in-
fluence of the cardiologist on the nurse and the various Hawthorne
effects may have diluted the benefit of nurse-led care. Unfortunately,
we did not document the reasons for deviating from the electronic
management advice.
Conclusion
Our trial failed to show that nurse-led care was superior to usual-
care in patients with atrial fibrillation. The results of the subgroup
analysis suggest that nurse-led care by an experienced team could be
clinically beneficial.
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Supplementary material is available at European Heart Journal online.
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